High-dose intravenous immunoglobulin may be an efficient treatment option for patients with late-onset high-grade immune effector cell-associated hematotoxicity refractory to stand... par Yousef Laham, Shimrit Ringelstein-Harlev, Daniel Kurnik, Riva Fineman, Dana Yehudai-Ofir, Lilach Bonstein, Noga Setter-Marco, Eyal Braun, Itai Ghersin, Tsila Zuckerman, Ofrat Beyar-Katz

Accéder au texte intégral